Dr.whitiss 20%
Carbamide Peroxide
Nibec Co., Ltd
Human Otc Drug
NDC 47649-1201Dr.whitiss 20% also known as Carbamide Peroxide is a human otc drug labeled by 'Nibec Co., Ltd'. National Drug Code (NDC) number for Dr.whitiss 20% is 47649-1201. This drug is available in dosage form of Gel, Dentifrice. The names of the active, medicinal ingredients in Dr.whitiss 20% drug includes Carbamide Peroxide - 20 g/100g . The currest status of Dr.whitiss 20% drug is Active.
Drug Information:
| Drug NDC: | 47649-1201 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Dr.whitiss 20% |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Carbamide Peroxide |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Nibec Co., Ltd |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Gel, Dentifrice |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CARBAMIDE PEROXIDE - 20 g/100g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | DENTAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 07 Jun, 2015 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 16 Jan, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part356 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Nibec Co., Ltd
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 1653117
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 31PZ2VAU81
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 47649-1201-2 | 4 SYRINGE in 1 PACKAGE (47649-1201-2) / 1 g in 1 SYRINGE (47649-1201-1) | 07 Jun, 2015 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Whitening of discolored teeth
Product Elements:
Dr.whitiss 20% carbamide peroxide povidone k90 glycerin water potassium nitrate carbamide peroxide hydrogen peroxide
Indications and Usage:
1. gingival and general oral heath should be confirmed before treatment. 2. brush your teeth before treatment. 3. follow your dentists instructions on how to load gel into your custom whitening tray. use no more than 1/3 to 1/2 of the syringe per tray. 4. insert whitening tray in the mouth over the teeth. seat the tray firmly agains the teeth. remove excess gel with clean finger or soft toothbrush.(rinse twice; do not swallow rinsed gel.) 5. unless directed otherwise by your dentist, wear dr.whitiss 10% for 8-10 hours or overnight, dr.whitiss 15% for 4-6 hours, dr.whitiss20% for 2-4 hours, and dr.whitiss 35% for 30 minutes. 6. if significant sensitivity occurs, stop treatment and consult dentist.
Warnings:
1) do not use on patient with sensitive to carbamide peroxide 2) do not use on patient with oral infection 3) no to be used by pregnant or lactating women or children under 18 years old 4) to be used under the supervision of a dentist 5) do not swallow this medication
Dosage and Administration:
For dental use only
Package Label Principal Display Panel:
Package label